KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
47 hedge funds and large institutions have $42.5M invested in KalVista Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
4% more funds holding
Funds holding: 45 → 47 (+2)
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
0% less capital invested
Capital invested by funds: $42.5M → $42.5M (-$25.8K)
0.66% less ownership
Funds ownership: 45.25% → 44.59% (-0.66%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$468K |
| 2 |
AFG
Albion Financial Group
Salt Lake City,
Utah
|
+$362K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$145K |
| 4 |
AHB
Abner Herrman & Brock
Jersey City,
New Jersey
|
+$117K |
| 5 |
OPPM
Opus Point Partners Management
New York
|
+$65.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$576K |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$408K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$354K |
| 4 |
Goldman Sachs
New York
|
-$183K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$150K |
KALV Hedge Fund Activity: Q4 2015 in Review
47 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2015, worth a combined $42.5M — down 0.06% from $42.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new KALV positions and 4 closed out — a net gain of 2 holders — while 14 added to existing stakes and 14 trimmed.
The largest buyer was Vanguard Group, adding an estimated $468K. The largest seller was Panagora Asset Management, exiting entirely with an estimated $576K sold.
- 47 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2015, up from 45 in Q3 2015.
- Funds reported $42.5M of KalVista Pharmaceuticals stock for Q4 2015, down 0.06% quarter-over-quarter.
- 6 funds opened new KalVista Pharmaceuticals positions in Q4 2015 and 4 closed out, a net change of +2 holders.
- The largest KalVista Pharmaceuticals buyer in Q4 2015 was Vanguard Group, an estimated $468K added.
- The largest KalVista Pharmaceuticals seller in Q4 2015 was Panagora Asset Management, an estimated $576K sold.
Based on aggregated 13F filings for Q4 2015.